QUALITY IN SPORT
eISSN 2450-3118 · Open Access · Peer-reviewed
apcz.umk.pl/QS Nicolaus Copernicus University in Toruń

SOBCZAK, Agata, KOWALCZYK, Maja, WOLFF, Magdalena, KREFT, Kalina, GŁUSZKIEWICZ, Lena, and WALDMAN, Anna. Impact of Commercialisation of Extreme Mountaineering on High-Altitude Hypoxia, Pharmacological Prophylaxis and Risk Management on Mount Everest: A Narrative Review. Quality in Sport. 2026;76:75522. https://doi.org/10.12775/QS.2026.76.75522

ARTICLE TIMELINE
Received: 20.08.2026. Revised: 30.08.2026. Accepted: 13.09.2026. Published: 23.09.2026.

The journal has been awarded 20 points in the parametric evaluation by the Polish Ministry of Higher Education and Science (Annex to the announcement of 05.01.2024, No. 32553). Unique Journal Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).
Punkty Ministerialne z 2019 – aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych). The authors declare no conflict of interest regarding the publication of this paper.

Impact of Commercialisation of Extreme Mountaineering on High-Altitude Hypoxia, Pharmacological Prophylaxis, and Risk Management on Mount Everest: A Narrative Review

Agata Sobczak
University Clinical Center in Gdańsk
Dębinki 7, 80-952 Gdańsk, Poland
https://orcid.org/0009-0009-0396-3578, agata.mar.gawron@gmail.com

Maja Kowalczyk
Karol Marcinkowski University Hospital in Zielona Góra
Zyty 26 65-046 Zielona Góra, Poland
https://orcid.org/0009-0000-0074-1405, maja.u.kowalczyk@gmail.com

Lena Głuszkiewicz
University Clinical Center in Gdańsk
Dębinki 7, 80-952 Gdańsk, Poland
https://orcid.org/0009-0009-3627-0364, lgluszkiewicz@uck.gda.pl

Magdalena Wolff
Karol Marcinkowski University Hospital in Zielona Góra
Zyty 26, 65-046 Zielona Góra, Poland
https://orcid.org/0009-0003-8972-0273, magda.wolff@o2.pl

Kalina Kreft
Karol Marcinkowski University Hospital in Zielona Góra
Zyty 26, 65-046 Zielona Góra, Poland
https://orcid.org/0009-0001-9584-7305 , kreft.kalina@gmail.com

Anna Waldman
Poznan University of Medical Sciences,
ul. Aleksandra Fredry 10, 61-701 Poznań, Poland
https://orcid.org/0009-0001-2332-1814, anna.waldman29@gmail.com

Corresponding Author
Agata Sobczak agata.mar.gawron@gmail.com

Abstract

Background: The commercialization of extreme high-altitude mountaineering on Mount Everest has fundamentally expanded access to the "death zone" (>8000 m), exposing non-acclimatized climbers to profound physiological vulnerabilities.

Aim: This narrative review synthesizes the pathophysiological consequences, pharmacological prophylaxis, and risk management challenges associated with summit-day crowding and extended static delays.

Materials and Methods: A systematic search of PubMed/MEDLINE, Google Scholar, Scopus, and Web of Science was conducted up to mid-2026. A total of 38 peer-reviewed publications evaluating extreme-altitude physiology and expedition logistics were selected for qualitative synthesis.

Results: While commercial expeditions reduce baseline mortality risk by 37%, crowding creates severe bottlenecks that exhaust finite supplemental oxygen. This trigger causes rapid multi-system collapse characterized by acquired long QT syndrome, hypoxia-driven inflammatory high-altitude pulmonary edema (HAPE), and severe dehydration. Furthermore, widespread prophylactic abuse of dexamethasone acts as a dangerous chemical substitute for acclimatization, masking deterioration and impairing rational judgment.

Conclusions: Mortality in the death zone represents a systemic failure of a fragile technological buffer rather than a direct consequence of commercialization itself. To mitigate these catastrophic risks, the industry must integrate targeted pre-expedition clinical screening, standardized medical literacy, and objective high-altitude triage protocols.

Keywords: Mount Everest, commercial mountaineering, high-altitude hypoxia, acute mountain sickness, crowding, pharmacological prophylaxis, risk management

1. Introduction

Human physiological limits have always been, and still are, being challenged by the environment. One of the stressors is high altitude. At the extreme altitude of Mount Everest (8,848 m a.s.l.), the barometric pressure drops to approximately one-third of its sea-level value, which results in a critical reduction of the partial pressure of inspired oxygen (PiO2). This environment, particularly the "death zone," the region above 8,000 meters, imposes an absolute physiological barrier beyond which human survival becomes time-limited. Progressive tissue oxygen deprivation, severe hypoxemia, and metabolic exhaustion make it impossible for the long-term survival of human beings. Historically, conquering these environmental parameters required meticulous scientific preparation. The core frameworks of modern altitude medicine and environmental physiology were heavily shaped by early methodical explorations. One of the most important landmarks in the history of high-altitude medicine is the contributions of Griffith Pugh, whose groundbreaking work has proven that conscientious oxygen logistics, balanced fluid intake, and optimal thermal protection were the definitive prerequisites for survival at extreme altitudes (Olatunji et al., 2024). Pugh's pioneering insights established a foundation for the understanding of high-altitude physiology, emphasizing that extreme mountaineering could only be safely conducted within strict boundaries determined by human adaptive tolerance, optimized nutritional support, and extended, methodical acclimatization schedules.

However, over the decades, the operational landscape of Himalayan mountaineering underwent a diametral shift, transitioning from elite, physically optimized sporting achievements to a commercialized sector of global adventure tourism. The scale of this change has been significant, characterized by accelerating growth in the number of expeditions and registered climbers in the Nepalese Himalaya, as documented by comprehensive analyses of the Himalayan Database (Huey et al., 2020; Westhoff et al., 2012). This unprecedented influx of mountaineers has fundamentally changed the demographic composition of individuals entering hypoxic environments, introducing a higher proportion of older and less experienced climbers (Huey et al., 2020). Concurrently, related research on regional trekking populations indicates a growing presence of tourists with distinct cardiovascular risk profiles advancing towards base camps (Haunolder et al., 2022). While it is frequently assumed that admitting recreational climbers with limited high-altitude technical training compromises traditional safety margins and transforms Everest into a public health concern due to overcrowded standard routes, empirical data contradict this narrative. Statistical modeling reveals that the commercial paradigm actually offsets individual vulnerabilities: participation in commercial expeditions lowers the odds of death compared with traditional ventures, and severe crowding during summit bids has not resulted in a statistically significant increase in mortality rates (Huey et al., 2020; Westhoff et al., 2012).

The core dilemma of modern commercial expeditions also stems from the profound differences between the genetic background of lowland clients and that of the indigenous high-altitude population, the Sherpas. The Sherpa people possess unique, highly specialized evolutionary adaptations that optimize tissue oxygen delivery under chronic hypoxic stress without inducing pathological erythrocyte overproduction (Bhandari & Cavalleri, 2019; Cai et al., 2026). These advantages are further modulated by unique patterns of convergent evolution observed in elite Himalayan and Andean cohorts. In these populations, angiogenesis, microvascular perfusion, and endothelial responses are distinctively altered to protect vital organs from ischemic injury (Ferraretti et al., 2025). Being born and growing up in a diametrically different environment, commercial climbers lack these adaptive phenotypes entirely. For a non-adapted individual, the only possibility of maintaining cell viability in the death zone is through heavy reliance on continuous, high-flow supplemental oxygen and other means of pharmacology. When technological measures, biological limitations, logistical friction of overcrowding, and prolonged static delays intersect, the physiological vulnerability of lowland climbers is profoundly exacerbated.

Therefore, this narrative review aims to synthesize the current pathophysiological evidence surrounding the commercialization of Mount Everest, critically examining how overcrowding, behavioral risk-taking, and severe educational deficits (Cerfontaine et al., 2022) transform acute hypoxemia into irreversible systemic emergencies.

2. Materials and Methods

2.1. Search Strategy and Data Sources

A comprehensive literature search was systematically conducted to identify peer-reviewed articles evaluating the physiological boundaries, risk management, and healthcare challenges induced by the commercialization of the "death zone" on Mount Everest. The electronic databases PubMed/MEDLINE, Google Scholar, Scopus, and Web of Science were searched. The search strategy targeted literature, including both foundational frameworks and recent advancements up to mid-2026. The specific search strings utilized combinations of Medical Subject Headings (MeSH) terms and free-text keywords using Boolean operators (AND/OR) as follows: ("Mount Everest" OR "Himalayan mountaineering" OR "death zone") AND ("commercialization" OR "crowding" OR "risk management" OR "logistics") AND ("hypoxia" OR "acute mountain sickness" OR "high-altitude pulmonary edema" OR "cardiac arrhythmia" OR "convergent evolution") AND ("pharmacological prophylaxis" OR "acetazolamide" OR "dexamethasone" OR "high-altitude athletes" OR "acute mountain sickness prevention")

2.2. Inclusion and Exclusion Criteria

To ensure thematic relevance and methodological rigor, explicit eligibility criteria were applied. *Inclusion Criteria:*

- Peer-reviewed original research, retrospective cohort studies, meta-analyses, and credible narrative reviews published in English.
- Studies investigating the physiological, cardiovascular, and cognitive effects of extreme altitude (>5000 m a.s.l., with specific emphasis on the death zone >8000 m a.s.l.).
- Literature addressing the management of high-altitude illnesses, commercial expedition ethics, and logistical frictions (e.g., overcrowding, supplemental oxygen dependency).
- Landmark historical papers providing foundational physiological context.

- Recent advancements in sports medicine and pharmacological prevention, specifically including English-language publications from prominent sports science journals (e.g., *Quality in Sport*, *Journal of Education, Health and Sport*) published between 2024 and 2026, to capture the latest prophylactic protocols and athlete-specific physiological data.

Exclusion Criteria:

- Non-peer-reviewed commentaries, editorials, popular media reports, and blog posts.
- Studies focusing exclusively on low-altitude hiking or general fitness unrelated to hypoxic environmental stressors.

2.3. Data Extraction and Synthesis

The initial screening of titles and abstracts was performed to filter out duplicates and irrelevant records. Following this, full-text articles were independently evaluated. A total of 38 key publications spanning from 2012 to 2026 were selected for final synthesis. The extracted data were thematically categorized into five primary dimensions:

1. The historical and scientific baseline of extreme altitude physiology.
2. The genetic and evolutionary disparities between indigenous populations and lowland climbers.
3. The clinical manifestations of acute high-altitude pathologies (including recent 2024–2026 data on cardiac risks, genomic adaptation, and advanced diagnostic models).
4. The pharmacological management of altitude illnesses, specifically contrasting the genuine acclimatization benefits of first-line agents with the perilous masking effects of corticosteroids.
5. The socio-managerial and ethical implications of commercial mountain tourism.

The synthesized evidence was qualitatively integrated to evaluate the physiological vulnerabilities of modern commercial climbers against the survival benefits provided by standardized expedition logistics. Ultimately, this review maps the transition of Mount Everest from a geographical sporting challenge to a complex operational environment, assessing whether its commercialization constitutes a public health crisis or a paradoxical model of mitigated extreme-altitude risk.

3. Mechanisms of High-Altitude Acclimatization vs. Commercial Timelines

3.1. Classical Acclimatization and Physiological Ascent Protocols

The preservation of cellular homeostasis during exposure to extreme altitude requires a coordinated sequence of adaptive responses to take place. Collectively, they are known as acclimatization. On a systemic level, acute survival depends heavily on the hypoxic ventilatory response (HVR). As peripheral chemoreceptors are triggered, hyperventilation occurs, leading to an increase in arterial oxygen tension (PaO2). Through this chain of actions, respiratory alkalosis is induced. Over a multi-week timeline, renal compensation via bicarbonate excretion stabilizes blood pH, and hematological shifts—driven by immediate erythropoietin secretion—gradually increase hemoglobin concentration and total red blood cell mass. All of this maximizes the oxygen-carrying capacity of the blood.

However, the efficacy of these physiological mechanisms is inextricably linked to the rate of ascent. Rapid initial ascent profiles can outpace the body's capacity for immediate gene expression and microvascular remodeling, initially increasing the risk of acute high-altitude pathologies. Investigating the direct clinical consequences of modern ascent dynamics, Zhao et al. (2024) systematically evaluated the prevalence and distinct clinical manifestations of acute mountain sickness (AMS) across a wide range of ascent protocols. Their findings reveal a dynamic and somewhat paradoxical clinical reality. While accelerated initial ascents trigger a higher baseline prevalence and severity of AMS compared to traditional, slower staging protocols at intermediate altitudes (e.g., 3650 m), this rapid ascent paradigm unexpectedly transitions into a protective factor upon further ascent. Zhao et al. (2024) demonstrated that climbers who underwent initial rapid mobilization experienced significantly attenuated AMS symptoms during subsequent ascents to higher altitudes (4400 m), whereas the slowly staging cohort suffered a marked spike in physiological distress. This exposes a critical nuance in high-altitude medicine: early, rapid exposure combined with intermediate staging may facilitate deeper physiological adaptation for subsequent extreme ascents, thereby challenging the rigid, traditional boundaries governing safe human movement in hypoxic environments (Zhao et al., 2024).

3.2. The Commercial Compression of Expedition Timelines and Survival Rates

Despite the rigid biological constraints of extreme altitude, the modern commercialization of mountaineering continues to introduce drastic changes to expedition schedules and ascent velocity. The high demand for shorter itineraries has led commercial agencies to aggressively compress the traditional 60-day Everest timeline, significantly diminishing traditional on-mountain acclimatization rotations. However, rather than sending unacclimatized lowlanders into the death zone to face lethal consequences, such temporal compression is facilitated by alternative physiological strategies. As highlighted by Burtscher et al. (2022), modern "rapid ascent" climbers compensate for the absence of mountain rotations through extensive at-home hypoxia conditioning (pre-acclimatization). By accumulating approximately 300 hours in normobaric hypoxic tents prior to departure, climbers successfully stimulate cellular acclimatization in advance, allowing them to tolerate rapid ascents safely.

Furthermore, the net survival effects of the commercial paradigm were exhaustively documented in a retrospective cohort study by Westhoff et al. (2012). Their statistical modeling of Himalayan mountaineering data revealed that commercialization does not represent a destabilizing factor for survival. On the contrary, participation in a commercial expedition is actually associated with a 37% lower odds of death relative to traditional ventures (Westhoff et al., 2012). Therefore, the structural evolution of the commercial guiding market—driven by collective knowledge, standardized routes, and the integration of advanced pre-acclimatization protocols—has significantly changed the ascent profile, successfully lessening the environmental hazards of compressed itineraries rather than exacerbating them.

3.3. Simulated Pre-Acclimatization and Normobaric Hypoxia Tents

In an effort to legitimize these truncated field schedules, the commercial sector has heavily adopted pre-expedition technological interventions. One of the best-known methods is normobaric hypoxia conditioning (HC) via hypoxic tents or chambers, which can be utilized even in the climber's home environment. This methodology seeks to stimulate essential ventilatory adaptations (and eventually erythropoiesis) prior to arriving in the Himalaya, thereby shifting the logistical timeline from the mountain to the pre-departure phase. By simulating high altitude at home, climbers can bypass the stage of natural acclimatization rotations.

The clinical efficacy and absolute temporal requirements of these simulated protocols, however, remain a focus of intense scientific assessment. Reviewing the institutional frameworks of hypoxic conditioning, Burtscher et al. (2022) demonstrated that while normobaric hypoxia conditioning can effectively modulate physiological parameters, its success is highly dependent on continuous, medically monitored exposures customized to large inter-individual variations in hypoxic tolerance. The precise operational requirements are further explained by Burtscher et al. (2026), whose research focused on the exact time requirements of pre-acclimatization at simulated altitudes. Their data indicate a strictly linear relationship between hypoxic exposure time and AMS prevention. While brief exposures offer only minor benefits, achieving comprehensive protection requires approximately 200 hypoxic hours (Burtscher et al., 2026). Recognizing this rigid biological threshold, modern commercial operators of rapid "Flash" expeditions do not rely on short-term exposures; instead, they mandate rigorous, long-term conditioning protocols, requiring clients to accumulate 200 to 300 hours of simulated hypoxia over 6 to 8 weeks prior to departure (Burtscher et al., 2022; Burtscher et al., 2026). Consequently, rather than underpreparing clients, these evidence-aligned commercial protocols successfully induce the necessary ventilatory acclimatization, successfully reducing the risks associated with accelerated ascents.

3.4. Gender-Specific Physiology and Alternative Survival Profiles

The assessment of high-altitude tolerance within commercial cohorts is further complicated by individual biological variables, particularly sex-specific physiological responses to hypoxia. As women have historically been underrepresented in mountaineering data, the distinct adaptive profiles of female climbers have become of interest to researchers. Burtscher et al. (2024) established comprehensive, specialized recommendations for women in mountain sports, meticulously evaluating their responses to both hypoxia training and conditioning. Their assessment indicates that while women exhibit comparable long-term acclimatization capacities to men, they display distinct ventilatory dynamics and fluid balance mechanisms under acute hypoxic stress (Burtscher et al., 2024).

When these heterogeneous cohorts encounter a disrupted or accelerated acclimatization pathway in the field, they are forced to deploy alternative, non-traditional survival profiles. Sharma et al. (2023) investigated specific survival strategies used to improve acclimatization and mitigate the physiological vulnerabilities of lowlanders exposed to high altitudes. Their analysis shows that in the absence of a natural, protracted staged ascent, rapid mobilization and survival rely heavily on structured pre-acclimatization techniques (such as simulated intermittent hypoxia exposure), carefully monitored fluid management to prevent AMS-inducing fluid retention, and the strategic prophylactic use of medications such as acetazolamide or dexamethasone. As noted by Westhoff et al. (2012), drawing upon historical boundaries established by Salisbury and Hawley (2011), the modern commercial era (beginning around 1990) relies not on extreme survival strategies but rather on the standardization of collective knowledge. Improvements in logistics, acclimatization strategies, weather forecasting, and a strict adherence to standard routes have radically changed the ascent profile. Consequently, despite the inclusion of less experienced climbers, participation in commercial expeditions successfully offsets individual vulnerabilities, operating with a mitigated risk of death compared to traditional, exploratory ventures.

4. The Pathophysiology of Crowding and Delays in the Death Zone

4.1. Epidemiological Shifts: Demographics, Commercialization, and Mortality Rates. The current state of extreme-altitude mountaineering on Mount Everest is defined by a profound epidemiological shift directly driven by commercialization. Historically, access to the "death zone"—the hyper-lethal environment extending above 8000 meters—was restricted to highly selected, physically optimized elite athletes. In contrast, modern commercial operations have expanded access, allowing wealth to substitute for technical progression and natural physiological selection.

The demographic consequences of this structural shift have been comprehensively quantified. Huey et al. (2020), in their extensive analysis of success and death rates on Mount Everest, demonstrated a profound demographic aging of the climbing population. Modern cohorts exhibit a heavily skewed distribution toward older clients with minimal prior experience in extreme wilderness high-altitude conditions.

However, the survival consequences of this structural shift contradict conventional expectations. This phenomenon is structurally reinforced by the retrospective cohort study by Westhoff et al. (2012), which maps the long-term trends of Himalayan mountaineering survival. Their statistical modeling provides empirical evidence that, while commercialization has systematically opened the death zone to less experienced subpopulations, it has actually mitigated their risks. Participation in a commercial climb is associated with a 37% lower odds of death relative to a traditional venture. Furthermore, when these structurally unadapted climbers encounter extensive bottlenecks on the localized fixed ropes, the interaction is not highly destructive, as is often assumed. Huey et al. (2020) demonstrated that despite a four-fold spike in overcrowding during summit bids, there is no statistically significant correlation between crowding and increased mortality or decreased summit success. The physical presence of a crowd does not convert minor delays into mass mortality events; instead, the modern commercial paradigm—relying on fixed ropes, advanced weather forecasting, and collective logistical knowledge—effectively buffers the physiological vulnerabilities of these non-selected climbers.

The sheer scale of this physiological vulnerability is frequently underestimated by commercial clientele. As highlighted by Olejarz et al. (2024), acute mountain sickness (AMS) can afflict up to 75% of individuals ascending above 2500 meters, with the central nervous system being the most exquisitely sensitive target of hypoxic stress. Crucially, empirical evidence shatters the dangerous commercial misconception that baseline physical conditioning mitigates this risk. Recent comprehensive assessments confirm that exceptional athletic fitness provides no meaningful protection against the onset of altitude illnesses, leaving even highly trained endurance athletes profoundly susceptible to AMS if ascent protocols are violated.

4.2. Meteorological Volatility and Ambient Oxygen Collapse

The physiological vulnerability of these crowded commercial cohorts is further amplified by severe meteorological volatility along the summit ridge. At an altitude exceeding 8500 meters, human cellular respiration operates on the absolute margin of viability. Static waiting within bottlenecks strips climbers of their capacity to actively time their movement, exposing them directly to extreme atmospheric depressions and severe thermal stress.

Szymczak et al. (2021) carefully mapped the death-zone weather extremes experienced during successful ascents, demonstrating that barometric pressure on Everest is not a static variable but instead undergoes rapid, high-amplitude depressions. The direct physical toll of this phenomenon is further explained by Matthews et al. (2020) in their assessment of human physiological boundaries ('Into Thick(er) Air?'). Their models show that weather-driven drops in barometric pressure cause a rapid contraction of the effective oxygen architecture, driving inspired oxygen availability down and effectively increasing the perceived elevation of the summit by up to 750 meters, which drastically limits maximal oxygen uptake (VO2 max).

Under these conditions, static delays in bottlenecks become highly dangerous. As noted by Szymczak et al. (2021), when a fatigued mountaineer is forced to stop, their heat production plummets precipitously, rapidly elevating the risk of severe hypothermia, which in turn increases oxygen consumption and accelerates fatigue. This physical exhaustion is compounded at the cellular level. As synthesized by Cai et al. (2026) in their overview of altitude hypoxia pathogenesis, the systemic drop in arterial oxygen tension triggers an immediate tissue energy crisis; reduced ATP synthesis impairs the Na+/K+ ATPase pump, initiating a rapid cascade of intracellular sodium and water retention that leads to cytotoxic edema. Thus, prolonged static exposure in the death zone transforms environmental hypoxia and thermal stress into irreversible cellular injury.

4.3. Myocardial Electrophysiological Disruption and Arrhythmias.

While high-altitude research has historically prioritized cerebral and pulmonary edemas, advanced clinical monitoring demonstrates that acute hypoxic exposure also profoundly challenges the electrophysiological stability of the myocardium. The combination of extreme hypoxia, autonomic conflict, and environmental stressors places significant strain on the cardiac conduction system.

A significant breakthrough in wilderness cardiology was achieved by Pilgrim et al. (2024), who evaluated the electrophysiological effects of extreme altitude using wearable continuous electrocardiogram (ECG) patches in climbers ascending Mount Everest. Their prospective field data uncovered a progressive prolongation of the heart-rate-corrected QT interval (QTc) from Everest Base Camp up to the summit. Strikingly, 59% of the participants experienced a significant QTc prolongation of 60 ms or more, and 24% developed acquired long QT syndrome (QTc ≥ 470 ms) above 7,900 meters. This severe delay in cardiac repolarization created a pro-arrhythmic substrate, leading to silent, asymptomatic ventricular tachyarrhythmias—including non-sustained and monomorphic sustained ventricular tachycardia—in several climbers. This highlights the profound electrophysiological stress of hypobaric hypoxia and respiratory alkalosis on the myocardium, which can trigger potentially malignant cardiac conduction anomalies without subjective awareness.

The underlying mechanism causing this electrical instability was further detailed by Pilgrim et al. (2024), who investigated the prevalence of QT prolongation in this same Everest cohort. Their electrophysiological assessments revealed that the hypobaric hypoxic environment induces a significant, progressive prolongation of the heart-rate-corrected QT interval (QTc). Nearly a quarter of the climbers developed an acquired Long QT Syndrome (LQTS) with a QTc exceeding 470 ms. This acquired prolongation creates a pro-arrhythmic substrate and is likely driven by respiratory alkalosis, hypothermia, and electrolyte imbalances—factors that the prophylactic use of acetazolamide can inadvertently exacerbate. However, as noted by Williams et al. (2022), the human heart generally demonstrates a strong capacity to adapt to hypoxia without obvious myocardial dysfunction. Therefore, while extreme altitude creates a severe proarrhythmic milieu, empirical data show that in healthy climbers, these electrophysiological disruptions often remain silent and are effectively mitigated by supplemental oxygen rather than inevitably progressing to sudden cardiac arrest.

4.4. Biomolecular Infiltration and Pulmonary Vascular Collapse

The severe hypoxemia characteristic of extreme altitudes serves as a primary hemodynamic trigger for fulminant high-altitude pulmonary edema (HAPE). In non-acclimatized lowland clients, the continuous drop in arterial oxygen tension triggers intense, uneven hypoxic pulmonary vasoconstriction (HPV), which severely spikes pulmonary artery systolic pressure and drives extreme capillary hydrostatic stress.

Advanced biomolecular mapping by Singh et al. (2025) has fundamentally transformed our understanding of this condition, uncovering specific integrative blood profiling and up-regulated inflammatory network signatures in patients suffering from HAPE. This research proves that HAPE is not simply a mechanical fluid overload; rather, prolonged severe hypoxemia activates a potent inflammatory cascade. Specifically, increased neutrophil abundance and the upregulation of hypoxia-driven inflammatory cytokines, such as Oncostatin M (OSM), trigger downstream pathways (e.g., MMP9) that actively degrade the extracellular matrix and compromise microvascular endothelial integrity. As this inflammatory network is hyper-stimulated, it causes fluid extravasation into the alveolar spaces.

The structural and diagnostic progression of this pulmonary collapse has been further evaluated using advanced machine learning by Yang et al. (2025). An assessment of a Grad-CAM interpretable deep learning model demonstrated that while severe, bilateral alveolar infiltration can be distinguished from normal radiographs, the model failed to reliably stratify intermediate, early-stage HAPE. This failure in precise severity stratification accentuates the insidious and subclinical nature of early microvascular leakage. Consequently, because early detection remains radiographically challenging, this subclinical leakage can unexpectedly accelerate into fulminant, suffocating HAPE, rendering emergency clinical field management exceptionally difficult.

4.5. Nutritional Deficits, Dehydration, and Severe Hemoconcentration

The multi-system pathophysiological collapse occurring in high-altitude bottlenecks is further worsened by severe metabolic and fluid imbalances. Standing immobile in a sub-zero, hypoxic bottleneck for up to 8 hours prevents climbers from accessing energy-dense nutrition or deploying hydration systems, which freeze instantly in the death zone.

The nutritional and hydration constraints governing these extreme environments were comprehensively reviewed by Karpęcka-Gałka and Frączek (2024). Their analysis demonstrates that extreme-altitude mountaineers exhibit massive respiratory fluid loss due to the continuous hyperventilation of dry, freezing air, combined with a profound decrease in appetite and thirst, known as mountain anorexia. When climbers are trapped in static queues, this fluid deficit triggers rapid, uncompensated plasma volume depletion and extreme hemoconcentration. Karpęcka-Gałka et al. (2023) documented these nutritional habits and fluid statuses among high-mountain climbers, confirming that inadequate fluid delivery under extreme conditions severely exacerbates hypovolemia and physical exhaustion.

This severe dehydration induced by crowding does not merely cause fatigue; rather, it drastically compounds the physiological stress on the entire cardiovascular system. By increasing blood viscosity, it heightens the risk of peripheral frostbite and microvascular complications. More critically, as documented by Pilgrim et al. (2024), dehydration drastically augments existing electrolyte imbalances—such as hypokalemia and hypocalcemia induced by hyperventilation and respiratory alkalosis. This severe metabolic disruption exacerbates the pro-arrhythmic milieu, drastically compounding the risk of the malignant cardiac arrhythmias that effectively seal the fate of the compromised commercial climber.

5. Educational Deficits, Sporting Ethics and Behavioral Risks

5.1. Hypoxia-Induced Cognitive Impairment and Self-Assessment Deficits

The educational crisis in modern high-altitude mountaineering is fundamentally compounded by the neurophysiological realities of extreme altitude. When commercial climbers are exposed to prolonged hypoxemia at extreme altitudes, the sustained decline in arterial oxygen saturation triggers cerebral metabolic changes that can impair cognitive performance.

However, the precise systemic impact of this exposure defies the common assumption of a total cognitive collapse. In a comprehensive meta-analysis evaluating the multi-dimensional effects of high-altitude mountaineering on human cognitive function, Li et al. (2023) found that executive function—the neurological locus responsible for logical reasoning, cognitive control, and decision-making—is actually surprisingly preserved, showing no significant negative impact. Instead, the primary measurable cognitive deficits induced by prolonged hypoxic exposure occur in the domains of motor speed and working memory.

In the practical context of a commercial expedition, this specific working memory impairment intersects dangerously with severe preexisting educational deficits. As demonstrated by Cerfontaine et al. (2022), the vast majority of amateur climbers possess minimal first aid knowledge regarding altitude illnesses, with only a fraction able to correctly recall the prevention strategies and symptoms of acute mountain sickness (AMS). Consequently, when climbers fail to recognize the early, subjective clinical signs of high-altitude cerebral edema (HACE) or critical hypoxemia, such as subtle ataxia or confusion, it is not primarily because hypoxia has dismantled their executive functioning. Rather, it is the combination of impaired memory function and a fundamental lack of baseline medical education that leaves them unaware of their physical decline. This severe educational void allows dangerous behavioral risk-taking, commonly referred to as "summit fever," converting preventable physiological distress into catastrophic medical emergencies.

5.2. Pre-Expedition Health Literacy and the Myth of Infallible Local Support

Extensive pre-expedition educational deficits heavily exacerbate this acute cognitive vulnerability. Modern commercial adventure tourism has detached participation from prerequisite mastery, allowing wealthy clients to substitute comprehensive health literacy with financial capital. Commercial agencies systematically minimize this pedagogical gap through marketing narratives that promise absolute safety under the absolute guardianship of indigenous guides and porters.

This reliance on an infallible local safety net, however, is heavily challenged by public health data. Koirala et al. (2018) conducted a critical cross-sectional study evaluating knowledge of high-altitude illness, practical training, and health attitudes among porters working in the Nepalese Himalaya. Their results revealed an alarming public health reality: a significant proportion of local support staff suffer from profound educational deficits regarding the underlying pathophysiology, prevention, and evidence-based treatment of severe high-altitude illnesses. Many local workers rely on traditional, unverified practices rather than standard clinical guidelines and frequently conceal their own escalating symptoms due to socioeconomic and commercial pressures. This structural insight shatters the commercial myth of an unconditional medical safety net; if the indigenous support staff upon whom clients place absolute reliance themselves lack standardized medical education, the safety margin of the entire expedition is critically compromised.

Furthermore, pre-expedition educational frameworks systematically fail to instruct clients on critical, non-traditional biomarkers of altitude susceptibility. Hou et al. (2026) demonstrated through a prospective observational study that severe insomnia symptoms experienced immediately prior to high-altitude exposure serve as an independent, high-amplitude predictive indicator for the development of acute mountain sickness (AMS). Despite its high predictive validity, pre-travel sleep architecture and its profound destabilizing impact on the body's stress response remain completely ignored within commercial pre-expedition briefing protocols. This leaves climbers unaware of how baseline sleep deprivation elevates sympathetic nervous system tone and HPA-axis activity, thereby increasing the allostatic load and drastically compounding environmental risk (Hou et al., 2026).

5.3. The Pharmacological "Gray Zone": Dexamethasone and Chemical Acclimatization. The confluence of severe educational deficits and commercial pressure has driven the emergence of a highly dangerous pharmacological "gray zone" in extreme mountaineering. Historically, high-altitude pharmacology was utilized strictly as an emergency resource to facilitate rapid descent during a life-threatening crisis. However, as highlighted by Wagner (2012), the commercial sector has increasingly normalized the widespread, off-label prophylactic use of potent prescription drugs to accelerate ascent timelines and enhance performance artificially.

This clinical mismanagement is particularly prominent with the aggressive, unmonitored use of corticosteroids. In a comprehensive narrative review of high-altitude clinical protocols, Burtscher et al. (2025) analyzed the explicit therapeutic and prophylactic boundaries of dexamethasone for the prevention of AMS, HACE, and HAPE. Their research confirms that while dexamethasone is highly effective at stabilizing the blood-brain barrier and attenuating vasogenic edema during rapid, emergency interventions, its systemic prophylactic administration by recreational climbers acts as a dangerous chemical substitute for genuine cellular acclimatization (Burtscher et al., 2025). By inducing subtle psychiatric adverse effects such as euphoria and hypomania, prophylactic dexamethasone creates a state of false physiological security, masking the climber's true physical deterioration and impairing rational decision-making in the death zone (Burtscher et al., 2025). This pharmacological mismanagement is vividly illustrated by the fundamental mechanistic differences between standard prophylactic agents. Antkiewicz et al.(2026) clarify that while acetazolamide actively facilitates true physiological acclimatization by inducing mild metabolic acidosis and stimulating ventilatory drive, dexamethasone offers no such adaptational benefit. Instead, dexamethasone operates purely by stabilizing the blood-brain barrier and suppressing inflammatory pathways. Consequently, when commercial climbers routinely abuse dexamethasone to accelerate their ascent, they are engaging in a dangerous pharmacological deception. The drug merely masks the evolving clinical reality of altitude illness without improving the underlying hypoxia tolerance, encouraging climbers to push deeper into the death zone despite grossly inadequate cellular acclimatization.

Furthermore, aggressive, unmonitored use exposes climbers to severe steroid toxicity (Wagner, 2012). Crucially, when the drug is discontinued or the supply is exhausted during an extended bottleneck, the suppressed hypoxic crisis rebounds, rendering the artificially supported climber highly vulnerable to a sudden resurgence of severe acute altitude illnesses. Consequently, researchers explicitly recommend against its prophylactic use in commercial trekking, emphasizing that natural acclimatization remains the only safe paradigm for recreational ascents (Burtscher et al., 2025).

5.4. The Erosion of Sporting Ethics and Technological Coercion

The shift toward chemical and technological dependence signifies a complex ethical dilemma that governs modern mountaineering. The commercialization of Mount Everest has challenged the classic sport ethos, which historically prioritized physical autonomy and a respectful submission to environmental constraints.

This ethical tension was critically analyzed by Wagner (2012), who examined the medical and sporting ethics of commercial mountaineering, focusing on the systemic use of drugs and supplemental oxygen. Wagner highlighted the paradox modern physicians face: while prescribing potent drugs acts as performance enhancement—blurring the lines of fair play and resembling doping in other sports—withholding them in hyper-lethal environments drastically increases the risk of mortality.

However, the assumption that pharmacological support automatically cheapens the intrinsic value of mountaineering has been recently challenged. Gordon and Dodds (2023) evaluated high-altitude biomedical enhancement through the philosophical prism of the World Anti-Doping Agency's "spirit of sport" criteria. Unlike critics who view this merely as a corporate erosion of ethics, Gordon and Dodds (2023) argue that the use of prophylactic drugs at extreme altitudes qualifies for a "therapeutic exemption". Because the severe hypoxic environment inherently masks and impairs a climber's natural abilities, these interventions allow for the actual exercise of those abilities rather than artificially replacing them. Consequently, they demonstrate that relying on such pharmacological support to survive the death zone does not undermine the climber's personal achievement (defined as success from ability), nor does it violate the true spirit of the sport, especially given the widespread structural acceptance of supplemental oxygen. Thus, the commercial mountaineering industry forces a reevaluation of behavioral risks, suggesting that maintaining physiological viability via technology is a necessary adaptation rather than a rigid ethical failure.

6. Medical Infrastructure and Emergency Logistics

6.1. Pre-Expedition Screening Deficiencies and Emergent Pathologies.

The absence of uniform, mandatory pre-expedition screening frameworks structurally undermines the management of critical medical emergencies on Mount Everest. Under the current commercial model, the verification of a climber's health status is largely decentralized to commercial agencies, which frequently prioritize financial enrollment over strict clinical selection. This operational gap allows individuals with significant, subclinical pathophysiological vulnerabilities to enter hypoxic environments.

Holthof et al. (2022) addressed this systemic public health vulnerability by conducting a detailed risk assessment of individuals with underlying lung disease exposed to moderate and high altitudes. Their data emphasize that subclinical respiratory pathologies—such as mild chronic obstructive pulmonary disease (COPD) or asthma—which remain manageable at sea level, limit a climber's ventilatory and gas exchange reserves. When exposed to terrestrial hypoxia, these limitations undergo rapid exacerbation, placing compromised individuals at risk of severe hypoxemia. In the absence of personalized risk stratification and rigorous pre-participation screening, including baseline pulmonary function tests, these unassessed vulnerabilities can unexpectedly accelerate respiratory failure, rapidly overwhelming the expedition's immediate medical resources.

Interestingly, the screening challenges in the modern high-altitude medical ecosystem have also been shaped by concerns regarding the long-term clinical sequelae of the global pandemic. Early speculations suggested that prior COVID-19 infections might drastically increase susceptibility to acute altitude illnesses due to overlapping hypoxemic features. However, Shen et al. (2026) conducted a prospective observational study that effectively debunked this assumption. Their epidemiological findings revealed that a history of mild-to-moderate COVID-19 infection is not significantly associated with an increased occurrence or severity of acute mountain sickness. This is because the underlying mechanisms are fundamentally distinct: while HAPE is driven by exaggerated hypoxic pulmonary vasoconstriction, COVID-19 is primarily a viral pneumonitis characterized by impaired hypoxic pulmonary vasoconstriction. Therefore, unless a climber suffers from severe, persistent post-COVID cardiopulmonary sequelae, prior infection does not independently compound the environmental risk, providing a critical, evidence-based refinement to modern triage and screening profiles.

Furthermore, the advancement of comprehensive predictive models offers a critical pathway to resolving these systemic screening deficiencies. As highlighted by Jia et al. (2026), a precise understanding of individualized risk factors enables the accurate prediction of a climber's susceptibility to acute high-altitude illness. Integrating such prognostic models allows for the development of personalized prevention and treatment strategies, which could fundamentally shift commercial expedition medicine from reactive emergency rescue to proactive risk mitigation. By establishing tailored prophylactic frameworks based on these predictive tools, medical personnel can ensure that clients with underlying vulnerabilities are adequately assessed and protected long before they face the extreme hypoxic stress of the death zone.

6.2. Field Medicine Realities and Advanced Therapeutic Interventions

When physiological failures manifest in the field, the responsibility for acute stabilization falls upon a highly fragmented and isolated medical infrastructure. The operational realities of delivering field medicine in the Solu-Khumbu and Manang regions are characterized by extreme geographic isolation and severe supply-chain vulnerabilities.

The structural and clinical challenges governing these high-altitude outposts were documented by Timilsina et al. (2024) through a systematic analysis of an operational season at the Himalayan Rescue Association (HRA) aid post. Their field data illustrate that wilderness medical stations operate under continuous resource strain, routinely managing infectious diseases and advanced altitude illnesses with limited diagnostic tools. Crucially, they highlight the severe logistical vulnerabilities of these outposts, such as prolonged interruptions to hydroelectric power supplies that force clinics to rely on emergency solar backups, even while running life-saving oxygen concentrators. These localized insights align with broader regional assessments by Dorji et al. (2023), who mapped the systemic challenges in Bhutan and Nepal. This comprehensive review highlighted that the remote locations of primary healthcare centers, combined with ill-equipped facilities and a lack of institutionalized high-altitude emergency training among some support staff, severely limit the capacity of base camp medical installations. Furthermore, emergency evacuations are frequently paralyzed because helicopters cannot fly at night or in adverse weather conditions that typically precipitate hypoxic crises.

Consequently, the implementation of advanced therapeutic interventions must be carefully balanced against these harsh environmental constraints. Addressing this issue, Bolotin et al.

(2025) evaluated a novel clinical approach in a randomized controlled trial (The HAPER CAPER Trial), investigating the efficacy of applying Continuous Positive Airway Pressure (CPAP) systems as an adjunct to high-flow oxygen for the treatment of high-altitude pulmonary edema. While CPAP is theoretically advantageous for cardiogenic pulmonary edema, clinical data demonstrated a counterintuitive reality for HAPE: the application of CPAP conferred no significant improvement in the time to clinical resolution compared to standard high-flow oxygen therapy alone. Because CPAP deployment requires significantly greater resource utilization—including vast amounts of oxygen to drive positive pressure or a dependency on reliable battery power for conventional machines—its use in austere environments is logistically burdensome. Therefore, Bolotin et al. (2025) concluded that standard high-flow oxygen therapy remains the optimal, highly effective choice, achieving the same life-saving benefits while preserving the critically limited resources of high-altitude medical outposts.

6.3. High-Altitude Triage and the Ethics of Extreme Rescue

The definitive crisis of emergency logistics on Mount Everest occurs when acute physiological collapse intersects with a bottleneck in the death zone. Above 8000 meters, human rescue operations function at the absolute limit of physical possibility. Helicopter-based medical evacuation is aerodynamically constrained by atmospheric density and is frequently rendered impossible by nighttime restrictions or extreme weather. Thus, rescue remains an extraordinarily labor-intensive, ground-based operation overwhelmingly dependent on the physical strength and exposure of indigenous support staff.

The profound logistical and moral dimensions of this crisis were addressed in an official position paper by the International Commission for Alpine Rescue (ICAR), authored by Ellerton et al. (2026). Rather than relying on traditional, binary moral judgments, the commission established that the extreme risks of the death zone require translating ethical considerations into a strict language of risk management. Drawing upon the ethical concept of the "Duty of Easy Rescue"—where saving a life is obligatory only if the cost and risk to the rescuer are minimal—the ICAR paper notes that the presence of extensive bottlenecks fundamentally alters this dynamic (Ellerton et al., 2026). When a climber suffers an acute medical crisis while trapped in a static, single-rope queue, the physical crowding, severe hypoxia, and harsh environmental exposure drastically elevate the risk to potential rescuers. Under these extreme conditions, attempting a rescue often transitions from a strict moral obligation to a "supererogatory" act—an action that is highly commendable but beyond the call of basic duty.

Furthermore, Ellerton et al. (2026) emphasize that commercialization has exacerbated a stark ethical inequality regarding who bears this risk. The burden of executing these high-risk extrications falls disproportionately on "subsistence mountain workers" (local guides and porters), a highly vulnerable cohort that accounts for nearly half of all fatalities on Everest, yet whose own access to rescue provision and fair risk assessment is frequently compromised by socio-economic pressures. Ultimately, the ICAR position paper underscores that while commercialization often obscures the rigid realities of the death zone, the safety of both clients and indigenous staff can only be improved if ad-hoc high-altitude rescues adopt the objective, risk-management protocols of organized professional rescue, recognizing that at extreme altitudes, physiological and environmental limits may legitimately supersede the moral capacity to save a life (Ellerton et al., 2026).

7. Discussion and Public Health Recommendations

7.1. Synthesis of the Pathophysiological and Commercial Cascade

The holistic synthesis of the evidence compiled in this review reveals that mortality and catastrophic medical crises on Mount Everest are not isolated, unpredictable environmental accidents. However, contrary to the popular narrative, they are not the inevitable result of commercial market forces directly compromising human safety. Instead, they represent the definitive endpoint of a systemic cascade that occurs when advanced logistical and technological infrastructure collapses, exposing unadapted individuals to rigid biological boundaries. As demonstrated by Westhoff et al. (2012), the commercialization of Himalayan mountaineering—through collective knowledge, fixed ropes, and supplemental oxygen—has actually mitigated baseline environmental hazards, reducing the odds of death by 37% relative to traditional ventures. The true vulnerability lies in the paradox of this modern safety net: it allows physiologically unadapted individuals to ascend safely. Still, it leaves them exquisitely vulnerable if the support network is disrupted.

This structural tension initiates long before climbers reach the base of the mountain. The contemporary commercial business model has systematically truncated traditional expedition schedules, relying heavily on artificial pre-acclimatization technologies. When rigorously executed over 200 to 300 hours, these normobaric hypoxia protocols successfully induce ventilatory acclimatization, effectively preparing clients for rapid ascents. However, this compressed timeline intersects with a critical absence of uniform, mandatory pre-participation medical screening. While recent evidence indicates that a history of mild-to-moderate COVID-

19 infection does not increase altitude illness susceptibility, highly vulnerable individuals with other subclinical respiratory pathologies are routinely granted access to extreme altitudes without proper physiological reserve assessments. Detached from rigorous prerequisite training, these climbers exhibit a profound deficit in health self-assessment literacy. Although extreme hypoxia does not paralyze executive functioning, it does impair working memory and motor speed. Consequently, the modern commercial climber enters the high-altitude environment as a physically dependent agent, relying not on intrinsic physiological resilience but entirely on a local support network and technological aids.

The crisis transitions from potential to acute only when this technological and logistical buffer fails in the death zone. While climbing data indicate that summit-day overcrowding does not directly increase overall mortality or decrease summit success, the static delays it causes can be highly lethal if they deplete supplemental oxygen supplies. Without the protective effect of bottled oxygen, the human body cannot maintain homeostasis while standing static at 8500 meters. The sudden, unmitigated exposure to extreme hypoxia during prolonged bottlenecks transforms manageable hypoxemia into a multi-system pathophysiological crisis. The lack of physical movement shuts down heat production, accelerating the onset of severe hypothermia. Concurrently, severe, uncompensated hypoxemia induces profound electrophysiological abnormalities; unbuffered by supplemental oxygen, climbers rapidly develop an acquired Long QT Syndrome, creating a pro-arrhythmic substrate. Simultaneously, the unabated hypoxic pulmonary vasoconstriction and systemic inflammatory cascade drive extreme capillary hydrostatic stress, eventually causing fluid extravasation into the alveoli and cerebral parenchyma. Thus, catastrophic events on Everest are ultimately triggered when the modern commercial buffer vanishes, forcing artificially supported lowlanders past their unassisted physiological breaking points.

The final breakdown occurs when the volume of these multi-system biological failures collides with the severe limitations of high-altitude emergency logistics. Wilderness medicine infrastructure in these remote regions operates under profound resource constraints and geographic isolation, which heavily restrict clinical capacity. When an acute medical crisis manifests in a congested, single-rope bottleneck, advanced therapeutic field interventions become logistically unviable. For instance, the deployment of CPAP systems for HAPE is precluded not merely by crowds but because it requires immense oxygen reserves and reliable power, rendering it no more effective than standard high-flow oxygen in such austere environments. Furthermore, when manual ground evacuation is physically blocked by the crowd, local guides and rescue organizations are not simply forced into 'utilitarian triage' dilemmas. Instead, this logistical impasse necessitates a shift toward strict, objective risk management. As outlined by the International Commission for Alpine Rescue (ICAR), the extreme hazards of the death zone negate the traditional 'Duty of Easy Rescue'. When physical crowding, severe hypoxia, and weather extremes drastically elevate the risk to potential rescuers—who are disproportionately indigenous mountain workers—attempting an extrication transitions from a moral obligation to a supererogatory act. Thus, while the commercial paradigm effectively buffers risk for the majority, it has simultaneously engineered an environment in which sudden physiological collapse at extreme altitudes often exceeds the ethical and practical limits of human rescue capabilities, reinforcing the absolute biological boundaries of survival.

7.2. Public Health and Institutional Recommendations

To dismantle this lethal cascade, the management of extreme high-altitude mountaineering must undergo an evidence-based paradigm shift. Rather than dismantling the commercial adventure tourism framework—which statistical modeling has actually shown to mitigate baseline mortality risks—the industry must be integrated into a strict public health and risk-management intervention framework. Citing the interdisciplinary scope of the *Journal of Education, Health and Sport (JEHS)*, the following three systemic countermeasures are urgently recommended for implementation by international climbing federations (UIAA) and ministries of tourism:

1. Targeted Medical Stratification Over Blanket Restrictions:

Governments and agencies must shift away from arbitrary prerequisites and focus on objective medical stratification. Empirical data explicitly demonstrate that prior high-altitude climbing experience does not correlate with reduced mortality rates in the death zone; thus, statutory experience mandates would only cause severe economic damage to local mountain communities without improving survival. Instead, authorities should mandate targeted clinical screenings. As recommended by Holthof et al. (2022), individuals with pre-existing or subclinical respiratory and cardiovascular conditions must undergo standardized pulmonary function tests (PFTs) and baseline risk assessments. Crucially, recent evidence confirms that a history of mild-to-moderate COVID-19 does not increase altitude susceptibility, streamlining the screening process to focus strictly on active, untreated cardiopulmonary vulnerabilities.

2. Institutionalization of Standardized Medical and Safety Literacy:

Climbers, guides, and highly vulnerable local support staff must be legally required to complete certified pre-participation training modules in high-altitude medicine and wilderness emergency care. As demonstrated by Cerfontaine et al. (2022), severe deficits in knowledge of first aid and rescue strategies persist across commercial cohorts. Education must focus on the early clinical signs of neurological and pulmonary edema, objective biomarker monitoring (e.g., daily field pulse oximetry trends), and the severe pathophysiological dangers associated with the prophylactic abuse of potent corticosteroids like dexamethasone, which mask symptoms and impair executive decision-making. Furthermore, institutional educational frameworks must strictly reinforce evidence-based ascent protocols. As emphasized by Choroszewicz et al. (2020), the fundamental 'climb high, sleep low' paradigm remains the cornerstone of non-pharmacological prevention. When compressed timelines or the inability to descend render natural acclimatization impossible, and pharmacological prophylaxis is deemed clinically necessary, safety guidelines must explicitly differentiate between the agents used. Institutions must promote the genuine adaptational benefits of acetazolamide as a proven, first-line prophylactic agent, while clearly communicating the severe masking risks of dexamethasone. To protect climbers from catastrophic, sudden-onset edema during static delays, the administration of dexamethasone should be strictly restricted to emergency rescue protocols and descent facilitation, rather than permitted as a routine prophylactic buffer for summit bids.

3. Implementation of Professional Risk-Management and Triage Frameworks: While data show that environmental crowding does not directly increase overall mortality during summit bids, the resulting logistical bottlenecks fundamentally cripple traditional rescue operations. Therefore, regulatory bodies must formally integrate the operational realities of the death zone into expedition planning. Following the guidelines established by the International Commission for Alpine Rescue (ICAR), commercial operators must adopt strict, objective risk-management protocols that supersede traditional emotional or moral rescue obligations. By establishing legally binding operational limits—such as mandatory supplemental oxygen reserves dedicated solely for extended static delays—the industry can protect both clients and the heavily burdened indigenous support staff from the catastrophic consequences of infrastructure breakdown in hyper-lethal environments.

8. Conclusions

The commercialization of Mount Everest has fundamentally transformed the nature of extreme high-altitude mountaineering, reshaping the demographic profile of climbers while systematically compressing vital biological adaptation timelines. However, as this narrative review demonstrates, the relationship between commercialization and mortality is deeply paradoxical. Contrary to the assumption that corporate management inherently compromises safety, empirical data confirm that the modern commercial paradigm—relying on fixed ropes, advanced weather forecasting, and structured logistics—actually mitigates baseline environmental hazards, reducing the odds of death relative to traditional ventures (Westhoff et al., 2012).

However, this statistical safety relies entirely on a fragile technological bubble. When this infrastructure is compromised, the physiological consequences are catastrophic. While data indicate that crowding within the death zone does not automatically spike mass mortality (Huey et al., 2020), it creates extended static delays that rapidly deplete finite supplemental oxygen reserves. Once this pharmacological and technological masking is exhausted, the unbuffered human body is exposed to an uncompromising physiological frontier. The resulting prolonged hypoxemia triggers a lethal cascade of myocardial electrophysiological disruption, fulminant alveolar and cerebral edema, and severe hypothermia that rapidly exhausts the body's remaining functional reserves.

Because the localized medical infrastructure and high-altitude rescue logistics are inherently unequipped to manage acute physiological collapse under such extreme environmental constraints, the burden of risk and rescue falls disproportionately on indigenous support staff. To protect both recreational participants and the socio-economic well-being of these highly vulnerable mountain workers, the international sports science and high-altitude medical communities must intervene. Rather than framing pharmacological support and oxygen strictly as violations of sporting ethics—since such interventions can legitimately serve as therapeutic exemptions in hyper-lethal environments (Gordon & Dodds, 2023)—the focus must shift toward rigorous, evidence-based risk management. Ultimately, while Mount Everest can be successfully managed as a commercial enterprise, it requires the enforcement of strict public health frameworks, targeted physiological screening, and equitable triage protocols, recognizing that beneath the commercial safety net, survival remains strictly governed by the unyielding laws of human biology.

Disclosure Section

Conceptualization: Agata Sobczak and Maja Kowalczyk;

Methodology: Agata Sobczak

Software: Maja Kowalczyk

Validation: Kalina Kreft., Lena Głuszkiewicz, and Anna Waldman

Formal analysis: Anna Waldman

Investigation: Kalina Kreft

Resources: Magdalena Wolff

Data curation: Magdalena Wolff

Writing—original draft preparation: Agata Sobczak

Writing—review and editing: Maja Kowalczyk and Lena Głuszkiewicz

Visualization: Magdalena Wolff

Supervision: Kalina Kreft

Project administration: Lena Głuszkiewicz

Funding: The article did not receive any funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: Not applicable

All authors have read and agreed to the published version of the manuscript.

The authors declare no conflict of interest.

During the preparation of this manuscript, the authors used AI tools solely for English language editing and stylistic refinement. After using this service, the authors reviewed and edited the content as needed and take full responsibility for the framework and accuracy of the publication.

References

1. Antkiewicz, M., Arczyńska-Antkiewicz, A., Czechowicz, P., Czechowicz, J., Zając, G., Drozd, M., Łobaza, P., Kudła, M., Krawczyk, A., Pawełczak, N., Kołkowicz, D., Kociuba, J., Kruczek, Z., Kurcińska, J., & Kurciński, S. (2026). Acute mountain sickness in mountaineers and high-altitude athletes: Pharmacological prevention and practical considerations. *Quality in Sport*, *58,* Article 72524. https://doi.org/10.12775/QS.2026.58.72524
2. Bhandari, S., & Cavalleri, G. L. (2019). Population history and altitude-related adaptation in the Sherpa. *Frontiers in Physiology*, *10,* Article 1116. https://doi.org/10.3389/fphys.2019.01116
3. Bolotin, T., Subedi, S., Dahal, S., Walker, C., Chung, K., Martz, A., Gemmel, D., Chopra, Q., & Donley, C. (2025). High altitude pulmonary edema response to continuous airway positive pressure: A randomized controlled trial: The HAPER CAPER Trial. *Academic Emergency Medicine*, *32*(11), 1215–1223. https://doi.org/10.1111/acem.70126
4. Burtscher, J., Gatterer, H., Beidleman, B. A., & Burtscher, M. (2025). Dexamethasone for prevention of AMS, HACE, and HAPE and for limiting impairment of performance after rapid ascent to high altitude: A narrative review. *Military Medical Research*, *12,* Article 48. https://doi.org/10.1186/s40779-025-00634-y
5. Burtscher, J., Hüfner, K., Gatterer, H., Pichler-Hefti, J., Hefti, U., Tannheimer, M., Kleinsasser, A., Hackett, P., & Burtscher, M. (2026). Time requirements of pre-acclimatization at simulated altitude to prevent acute mountain sickness. *Journal of Travel Medicine*, *33*(3), Article taag009. https://doi.org/10.1093/jtm/taag009
6. Burtscher, J., Raberin, A., Brocherie, F., Malatesta, D., Manferdelli, G., Citherlet, T., Krumm, B., Bourdillon, N., Antero, J., Rasica, L., Burtscher, M., & Millet, G. P. (2024). Recommendations for women in mountain sports and hypoxia training/conditioning. *Sports Medicine*, *54*(4), 795–811. https://doi.org/10.1007/s40279-023-01970-6
7. Burtscher, M., Millet, G. P., & Burtscher, J. (2022). Hypoxia conditioning for high-altitude pre-acclimatization. *Journal of Science in Sport and Exercise*, *4*(4), 331–345. https://doi.org/10.1007/s42978-021-00150-0
8. Cai, C., Ni, G., Chen, L., Deng, C., Chai, S., Wang, R., Zhang, R., Luo, F., & Ge, R.-L. (2026). Altitude hypoxia and hypoxemia: Pathogenesis and management. *Signal*

Transduction and Targeted Therapy, *11*, Article 27. https://doi.org/10.1038/s41392-025-02531-1

9. Cerfontaine, C., Apel, C., Bertsch, D., Grass, M., Haunolder, M., Hundt, N., Jäger, J., Kühn, C., Museol, S., Timmermann, L., van der Giet, M., van der Giet, S., Wernitz, K., Schöffl, V., Morrison, A., & Küpper, T. (2022). Companion rescue and risk management of trekkers on the Everest trek, Solo Khumbu Region, Nepal. *International Journal of Environmental Research and Public Health*, *19*(23), Article 16288. https://doi.org/10.3390/ijerph192316288
10. Choroszewicz, P., Dobosiewicz, A. M., & Badiuk, N. (2020). Acetazolamide in prevention of altitude disease. *Pedagogy and Psychology of Sport*, *6*(2), 95–103. https://doi.org/10.12775/PPS.2020.06.02.009
11. Dorji, T., Giri, S., Tshering, U., LeVine, S., Tshering, U., Chhetri, S., Dhakal, N., Gaikwad, S. N., Flaherty, G. T., Lucero-Prisno, D. E., III, & McIntosh, S. (2023). Challenges in the management of high-altitude illnesses and emergencies in Bhutan and Nepal. *Travel Medicine and Infectious Disease*, *56*, Article 102660. https://doi.org/10.1016/j.tmaid.2023.102660
12. Ellerton, J., Sheets, A., McLaughlin, K., & Paal, P. (2026). Rescue at extreme altitude: Managing the ethical considerations in the language of risk management. An International Commission for Alpine Rescue position paper. *High Altitude Medicine & Biology*, *27*(2), 117–122. https://doi.org/10.1177/15578682251400732
13. Ferraretti, G., Rill, A., Abondio, P., Smith, K., Ojeda-Granados, C., De Fanti, S., Alberti, M., Izzi, M., Sherpa, P. T., Cocco, P., Tiriticco, M., Di Marcello, M., Dezi, A., Gnecchi-Ruscone, G. A., Natali, L., Corcelli, A., Marinelli, G., Garagnani, P., Peluzzi, D., Sazzini, M. (2025). Convergent evolution of complex adaptive traits modulates angiogenesis in high-altitude Andean and Himalayan human populations. *Communications Biology*, *8*, Article 377. https://doi.org/10.1038/s42003-025-07813-6
14. Gordon, E. C., & Dodds, C. (2023). High altitude, enhancement, and the 'spirit of sport'. *Journal of the Philosophy of Sport*, *50*(1), 63–82. https://doi.org/10.1080/00948705.2023.2168679
15. Haunolder, M., Apel, C., Bertsch, D., Grass, M., Hundt, N., Jäger, J., Kühn, C., Museol, S., Timmermann, L., van der Giet, M., van der Giet, S., Wernitz, K., Cerfontaine, C., Schöffl, V., Morrison, A., & Küpper, T. (2022). Cardiovascular risk profiles and pre-existing health conditions of trekkers in the Solu-Khumbu region, Nepal. *International*

Journal of Environmental Research and Public Health, *19*(24), Article 16388. https://doi.org/10.3390/ijerph192416388

16. Holthof, K., Bridevaux, P.-O., & Frésard, I. (2022). Underlying lung disease and exposure to terrestrial moderate and high altitude: Personalized risk assessment. *BMC Pulmonary Medicine*, *22*, Article 187. https://doi.org/10.1186/s12890-022-01979-z
17. Hou, S., Jiang, J., Huang, Y., Liang, Y., Zhou, X., & Li, L. (2026). The independent predictive effect of insomnia symptoms before high-altitude exposure on acute mountain sickness: An observational study of healthy volunteers at 2726 m. *Frontiers in Psychiatry*, *17*, Article 1765494. https://doi.org/10.3389/fpsyt.2026.1765494
18. Huey, R. B., Carroll, C., Salisbury, R., & Wang, J.-L. (2020). Mountaineers on Mount Everest: Effects of age, sex, experience, and crowding on rates of success and death. *PLoS ONE*, *15*(8), Article e0236919. https://doi.org/10.1371/journal.pone.0236919
19. Jia, N., Chen, C., Chen, Q., Liu, J., Shen, Z., Liu, Y., Pei, C., Wang, Y., Huang, D., Wang, F., He, Y., & Wang, Z. (2026). Acute high-altitude illness: Risk factors, susceptibility prediction, and personalized prevention and treatment. *Frontiers in Medicine*, *12*, Article 1735083. https://doi.org/10.3389/fmed.2025.1735083
20. Karpęcka-Gałka, E., & Frączek, B. (2024). Nutrition, hydration, and supplementation considerations for mountaineers in high-altitude conditions: A narrative review. *Frontiers in Sports and Active Living*, *6*, Article 1435494. https://doi.org/10.3389/fspor.2024.1435494
21. Karpęcka-Gałka, E., Mazur-Kurach, P., Szyguła, Z., & Frączek, B. (2023). Diet, supplementation and nutritional habits of climbers in high mountain conditions. *Nutrients*, *15*(19), Article 4219. https://doi.org/10.3390/nu15194219
22. Koirala, P., Wolpin, S. E., & Peterson, J. T. (2018). High altitude illness: Knowledge, practice, and attitudes of porters in Nepal. *Wilderness & Environmental Medicine*, *29*(4), 431–436. https://doi.org/10.1016/j.wem.2018.06.002
23. Li, L., Zhou, Y., Zou, S., & Wang, Y. (2023). The effects of high-altitude mountaineering on cognitive function in mountaineers: A meta-analysis. *International Journal of Environmental Research and Public Health*, *20*(6), Article 5101. https://doi.org/10.3390/ijerph20065101
24. Matthews, T., Perry, L. B., Lane, T. P., Elmore, A. C., Khadka, A., Aryal, D., Shrestha, D., Tuladhar, S., Baidya, S. K., Gajurel, A., Potocki, M., & Mayewski, P. A. (2020). Into thick(er) air? Oxygen availability at humans' physiological frontier on Mount Everest. *iScience*, *23*(12), Article 101718. https://doi.org/10.1016/j.isci.2020.101718

25. Olatunji, M. A., Cornish, S., Gardiner, P., & Giesbrecht, G. G. (2024). Contributions of Griffith Pugh to success on Mt. Everest and his impact on the advancement of altitude and environmental physiology. *Wilderness & Environmental Medicine*, *35*(3), 366–373. https://doi.org/10.1177/10806032241259499
26. Olejarz, Z., Nowak, K., Drygała, Z., Wyrwał, J., Zielińska, Z., Słowik, M., Nowak, K., Nieć, M., Gierlach, K., & Krasuska, M. (2024). Examination of novel diagnostic approaches and contemporary strategies for preventing acute mountain sickness. *Journal of Education, Health and Sport*, *54*, 141–157. https://doi.org/10.12775/JEHS.2024.54.011
27. Pilgrim, T., Ryffel, C., Sherpa, P. P., Sherpa, T., Sherchand, O., Galuszka, O., Odening, K. E., Rothenbühler, M., Reichlin, T., & Sherpa, K. (2024). QT prolongation and acquired long QT syndrome in climbers on Mount Everest. *JACC: Clinical Electrophysiology*, *10*(11), 2509–2511. https://doi.org/10.1016/j.jacep.2024.07.012
28. Salisbury, R., & Hawley, E. (2011). *The Himalaya by the numbers: A statistical analysis of mountaineering in the Nepal Himalaya*. Vajra Publications.
29. Sharma, P., Mohanty, S., & Ahmad, Y. (2023). A study of survival strategies for improving acclimatization of lowlanders at high-altitude. *Heliyon*, *9*(4), Article e14929. https://doi.org/10.1016/j.heliyon.2023.e14929
30. Shen, T.-C., Lin, M.-C., Chuang, B.-K., Haivangang, B., & Lu, S.-F. (2026). Association between prior COVID-19 infection and acute mountain sickness on Jade Mountain: A prospective observational study (2023−2024). *Journal of Infection and Public Health*, *19*(4), Article 103152. https://doi.org/10.1016/j.jiph.2026.103152
31. Singh, K., Kumar G., K., Ali, M., Choudhary, R., Khadia, M., Rabyang, S., Thinlas, T., Kumar, R., & Mishra, A. (2025). Integrative blood profiling uncovers inflammatory network signatures in high-altitude pulmonary edema. *Bioscience Reports*, *45*(12), Article BSR20253746. https://doi.org/10.1042/bsr20253746
32. Szymczak, R. K., Marosz, M., Grzywacz, T., Sawicka, M., & Naczyk, M. (2021). Death zone weather extremes mountaineers have experienced in successful ascents. *Frontiers in Physiology*, *12*, Article 696335. https://doi.org/10.3389/fphys.2021.696335
33. Timilsina, S., Hillwood, G. E., Thwaites, G. E., Thwaites, C. L., & Bhandari, T. (2024). A season at the Himalayan Rescue Association Aid Post in Manang. *Wilderness & Environmental Medicine*, *35*(3), 308–313. https://doi.org/10.1177/10806032241257923

34. Wagner, D. R. (2012). Medical and sporting ethics of high altitude mountaineering: The use of drugs and supplemental oxygen. *Wilderness & Environmental Medicine*, *23*(3), 205–206. https://doi.org/10.1016/j.wem.2012.03.011
35. Westhoff, J. L., Koepsell, T. D., & Littell, C. T. (2012). Effects of experience and commercialisation on survival in Himalayan mountaineering: Retrospective cohort study. *BMJ, 344*, Article e3782. https://doi.org/10.1136/bmj.e3782
36. Williams, A. M., Levine, B. D., & Stembridge, M. (2022). A change of heart: Mechanisms of cardiac adaptation to acute and chronic hypoxia. *The Journal of Physiology*, *600*(18), 4089–4104. https://doi.org/10.1113/JP281724
37. Yang, Y., Yu, H., Xiang, Q., Wu, J., Li, J., Du, F., Yang, Y., & Wang, P. (2025). Assessment of a Grad-CAM interpretable deep learning model for HAPE diagnosis: Performance and pitfalls in severity stratification from chest radiographs. *BMC Medical Informatics and Decision Making*, *25*, Article 402. https://doi.org/10.1186/s12911-025-03256-5
38. Zhao, C., Zhao, X., Ma, Y., Liu, Y., Chen, R., & Sha, L. (2024). Dynamics in the prevalence and clinical manifestations of acute mountain sickness of different ascent protocols during high altitudes exposure. *Frontiers in Public Health*, *12*, Article 1472935. https://doi.org/10.3389/fpubh.2024.1472935